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Abstract
Aims/hypothesis To date, the molecular function of most of
the reported type 2 diabetes-associated loci remains un-
known. The introduction or removal of cytosine–phos-
phate–guanine (CpG) dinucleotides, which are possible
sites of DNA methylation, has been suggested as a potential
mechanism through which single-nucleotide polymor-
phisms (SNPs) can affect gene function via epigenetics.
The aim of this study was to examine if any of 40 SNPs
previously associated with type 2 diabetes introduce or
remove a CpG site and if these CpG-SNPs are associated
with differential DNA methylation in pancreatic islets of 84
human donors.
Methods DNAmethylation was analysed using pyrosequencing.
Results We found that 19 of 40 (48%) type 2 diabetes-
associated SNPs introduce or remove a CpG site.
Successful DNA methylation data were generated for 16
of these 19 CpG-SNP loci, representing the candidate genes
TCF7L2, KCNQ1, PPARG, HHEX, CDKN2A, SLC30A8,
DUSP9, CDKAL1, ADCY5, SRR, WFS1, IRS1, DUSP8,
HMGA2, TSPAN8 and CHCHD9. All analysed CpG-SNPs
were associated with differential DNA methylation of the
CpG-SNP site in human islets. Moreover, six CpG-SNPs,
representing TCF7L2, KCNQ1, CDKN2A, ADCY5, WFS1
and HMGA2, were also associated with DNA methylation of
surrounding CpG sites. Some of the type 2 diabetes CpG-SNP
sites that exhibit differential DNA methylation were further
associated with gene expression, alternative splicing events
determined by splice index, and hormone secretion in the
human islets. The 19 type 2 diabetes-associated CpG-SNPs
are in strong linkage disequilibrium (r2>0.8) with a total of
295 SNPs, including 91 CpG-SNPs.
Conclusions/interpretation Our results suggest that the
introduction or removal of a CpG site may be a molec-
ular mechanism through which some of the type 2
diabetes SNPs affect gene function via differential
DNA methylation and consequently contributes to the
phenotype of the disease.
Keywords Alternative splicing . CpG-SNP . DNA
methylation . Epigenetics . Glucagon . Human pancreatic
islets . Insulin secretion . SNP .Splice index .Type2diabetes
Abbreviations
CpG Cytosine–phosphate–guanine
GWAS Genome-wide association study
LD Linkage disequilibrium
SI Stimulation index
SNAP SNP annotation and proxy search
SNP Single-nucleotide polymorphism
Introduction
Type 2 diabetes is a heterogeneous disease caused by a
complex interplay between multiple genetic, epigenetic
and environmental factors [1]. Attempts at elucidating the
genetic mechanisms behind this disease have identified ap-
proximately 40 single-nucleotide polymorphisms (SNPs)
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that show genome-wide associations with type 2 diabetes
[2]. However, evidence for how these SNPs predispose to
type 2 diabetes is still scarce and is only available for a few
variants that mainly affect insulin secretion and sensitivity
[3]. Understanding the molecular mechanisms through
which these SNPs exert an effect on their target genes is
not an easy task, especially as most of them are non-coding
SNPs [2]. To further understand the pathogenesis of the
disease, additional studies are required that link these
SNPs with their molecular and biological functions.
Recent studies from our group and others have shown
that epigenetic modifications such as DNA methylation and
histone modifications may affect the pathogenesis of type 2
diabetes [4–9]. In differentiated mammalian cells, DNA
methylation mainly takes place at a cytosine in a cytosine–
phosphate–guanine (CpG) dinucleotide [10] and increased
DNA methylation has been associated with transcriptional
silencing [11]. In a previous study, we showed that genetic,
epigenetic and non-genetic factors integrate to influence the
expression of a candidate gene for type 2 diabetes in human
skeletal muscle [12]. We identified a SNP near NDUFB6
that introduces a CpG site and this CpG-SNP was associated
with increased DNA methylation, decreased gene expres-
sion, and insulin resistance in the muscle of elderly, but not
young, individuals [12]. Moreover, a recent study has sug-
gested that CpG-SNPs may affect the expression of target
genes by interfering with the binding of certain proteins
[13]. However, to our knowledge the role of CpG-SNPs
associated with type 2 diabetes has not been examined in
human pancreatic islets.
Therefore, the aim of this study was to examine if 40 SNPs
previously associated with type 2 diabetes [2] introduce or
remove possible DNA methylation sites – CpG sites – and if
these CpG-SNPs are associated with differential DNA meth-
ylation and subsequently affect gene expression, alternative
splicing events and hormone secretion in human pancreatic
islets.
Methods
Human pancreatic islet donors Pancreatic islets from 84
deceased non-diabetic donors were provided by the Nordic
Network for Islet Transplantation, Uppsala University.
Clinical characteristics of these islet donors are given in
Table 1. The donor before death or her/his relatives on
admission to intensive care unit gave their consent to donate
organs and the local ethics committees approved the proto-
cols. Islet culture and nucleic acid purification were per-
formed as described previously [7].
SNP selection and identification of CpG-SNPs The selec-
tion criterion for SNPs was an association with type 2
diabetes identified by major genome-wide association stud-
ies (GWASs) as reported by McCarthy [2]. To determine if
the selected SNPs were CpG-SNPs, the DNA sequences of
the variants were retrieved from the dbSNP database
(www.ncbi.nlm.nih.gov/snp/, on or after 03 July 2011). A
SNP was considered to be a CpG-SNP if it introduces or
removes a CpG site (Table 2). As a result, 19 SNPs fulfilled
our criteria of being CpG-SNPs that show genome-wide
association with type 2 diabetes. DNA sequences of these
19 CpG-SNPs and surrounding regions were then retrieved
from University of California, Santa Cruz Human Genome
Browser (UCSC) – hg18 assembly.
A flow chart of the study design and SNP selection can
be seen in Fig. 1.
DNA methylation assay design To analyse DNA methyla-
tion of the 19 selected CpG-SNP sites, pyrosequencing PCR
and sequencing primers were designed for the forward
strand using the PyroMark Assay design Software 2.0
(Qiagen, Hilden, Germany) (electronic supplementary ma-
terial [ESM] Table 1). The reverse or forward primer was
biotinylated at its 5′ end. When possible, CpG sites sur-
rounding the CpG-SNP of interest were also analysed.
Problems caused by sequence characteristics that resulted
in amplicons that were too long or too many CpG sites in the
primer sequences resulted in failure of the assay design for
rs5219 (KCNJ11) (Fig. 1).
DNA methylation analysis Bisulfite conversion of 500 ng
genomic DNA from human pancreatic islets was performed
using the EpiTect Bisulfite Kit (Qiagen) according to the
manufacturer’s instructions. Bisulfite-converted DNA was
amplified by PCR using the PyroMark PCR kit (Qiagen)
and the designed primers (ESM Table 1). Pyrosequencing
was performed using the PSQ HS96A (Biotage, Uppsala,
Sweden) and PyroMark Gold CDT kit (Qiagen) or using
PyroMark Q96ID and the PyroMark Gold Q96 kit (Qiagen),
all according to the manufacturer’s instructions. Data anal-
ysis was performed using the Pyro Q-CpG 1.0.9 and PSQ
HS96A 1.2 software (Biotage) or the PyroMark Q96 (ver-
sion 2.5.8) software (Qiagen). Only data that passed a qual-
ity check or had medium quality were included in the
analysis and as a result the following assay was excluded:
Table 1 Characteristics of the human pancreatic islet donors





Data are presented as mean ± SD
HbA1c was measured with the Mono-S method
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Table 2 SNPs associated with type 2 diabetes identified by GWAS
SNP ID Candidate gene Risk allele Chr. SNP position (build 37.1) SNP location Reference
CpG-SNPs where risk alleles remove a CpG site (n=8)
rs5945326 DUSP9a A X 152899922 Intergenic Voight et al (2010) [20]
rs564398 CDKN2Aa A 9 22029547 Intergenic Zeggini et al (2007) [21]
rs11708067 ADCY5a A 3 123065778 Intron Dupuis et al (2010) [22]
rs1801214 WFS1a T 4 6303022 Cds-synon Voight et al (2010) [20]
rs2334499 DUSP8a A 11 1696849 Intergenic Kong et al (2009) [23]
rs7578326 IRS1a A 2 227020653 Intergenic Voight et al (2010) [20]
rs5219 KCNJ11b T 11 17409572 Cds-nonsynon Scott et al (2007) [24]
rs1801282 PPARGa C 3 12393125 Cds-nonsynon Scott et al (2007) [24]
CpG-SNPs where risk alleles introduce a CpG site (n=11)
rs13292136 CHCHD9a C 9 81952128 Intergenic Voight et al (2010) [20]
rs7901695 TCF7L2a G 10 114754088 Intron Zeggini et al (2007) [21]
rs7754840 CDKAL1a C 6 20661250 Intron Scott et al (2007) [24]
rs391300 SRRa G 17 2216258 Intron Tsai et al (2010) [25]
rs5015480 HHEXa G 10 94465559 Intergenic Voight et al (2010) [20]
rs13266634 SLC30A8a G 8 118184783 Cds-nonsynon Sladek et al (2007) [26]
rs4457053 ZBED3c G 5 76424949 Intergenic Voight et al (2010) [20]
rs7961581 TSPAN8a C 12 71663102 Intergenic Zeggini et al (2008) [27]
rs1531343 HMGA2a C 12 66174894 Intergenic Voight et al (2010) [20]
rs2237895 KCNQ1a C 11 2857194 Intron Yasuda et al (2008) [28]
rs12779790 CDC123c G 10 12328010 Intergenic Zeggini et al (2008) [27]
Non-CpG SNPs (n=21)
rs243021 BCL11A A 2 60584819 Intergenic Voight et al (2010) [20]
rs10830963 MTNR1B G 11 92708710 Intron Dupuis et al (2010) [22]
rs7578597 THADA T 2 43732823 Missense Zeggini et al (2008) [27]
rs17584499 PTPRD T 9 8879118 Intron Tsai et al (2010) [25]
rs10923931 NOTCH2 T 1 120517959 Intron Zeggini et al (2008) [27]
rs7593730 RBMS1 C 2 161171454 Intron Qi et al (2010) [29]
rs4607103 ADAMTS9 C 3 64711904 Intergenic Zeggini et al (2008) [27]
rs1470579 IGF2BP2 C 3 185529080 Intron Voight et al (2010) [20]
rs864745 JAZF1 T 7 28180556 Intron Zeggini et al (2008) [27]
rs972283 KLF14 G 7 130466854 Intergenic Voight et al (2010) [20]
rs896854 TP53INP1 T 8 95960511 Intron Voight et al (2010) [20]
rs1552224 CENTD2 A 11 72433098 Intron Voight et al (2010) [20]
rs7957197 HNF1A T 12 121460686 Intron Voight et al (2010) [20]
rs11634397 ZFAND6 G 15 80432222 Intergenic Voight et al (2010) [20]
rs8042680 PRC1 A 15 91521337 Intron Voight et al (2010) [20]
rs9939609 FTO A 16 53820527 Intron Frayling et al (2007) [30]
rs4607517 GCK A 7 44235668 Intergenic Dupuis et al (2010) [22]
rs2191349 DGKB T 7 15064309 Intergenic Dupuis et al (2010) [22]
rs780094 GCKR C 2 27741237 Intron Dupuis et al (2010) [22]
rs340874 PROX1 C 1 214159256 Intergenic Dupuis et al (2010) [22]
rs4430796 HNF1B G 17 36098040 Intron Voight et al (2010) [20]
a Analysed CpG-SNPs
b Assay design problems
c Failed assay
Chr., chromosome; Cds-synon., coding-synonymous; Cds-nonsynon., coding-nonsynonymous
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rs12779790 (CDC123) (Fig. 1). Moreover, the assay for
rs4457053 (ZBED3) failed PCR amplification and hence
was also excluded.
Genotyping analysis Islet donors were genotyped for the 16
CpG-SNPs for which we retrieved DNA methylation data.
The following 12 SNPs were genotyped using the
HumanOmniExpressBeadChip and iScan system (Illumina,
San Diego, CA, USA) according to the manufacturer’s
instructions: rs5015480, rs7901695, rs391300, rs11708067,
rs7754840, rs13266634, rs564398, rs5945326, rs7961581,
rs2237895, rs1801282 and rs2334499. Four SNPs
(rs13292136, rs7578326, rs1531343 and rs1801214) were
not included on the Illumina chip and were therefore geno-
typed using TaqMan allelic discrimination assays on the
ABI7900 platform (assay IDs: C__11871167_10,
C__29270128_10, C__1692218_10 and C__8841076_10;
Applied Biosystems, Foster City, CA, USA). Furthermore,
three CpG-SNPs, rs4712523, rs3821943 and rs12778642,
which are in strong linkage disequilibrium (LD) with the three
type 2 diabetes CpG-SNPs rs7754840, rs1801214 and
rs5015480, respectively, were genotyped using the
HumanOmniExpressBeadChip and iScan system (Illumina).
Genotype frequencies were in Hardy–Weinberg equilibrium.
The genotype data analysed with either the Illumina chip or
TaqMan assays showed 100% concordance with the pyrose-
quencing genotype data.
Associations between CpG-SNPs and DNA methylation The
effects of the SNPs on DNA methylation of the CpG-
SNP sites and surrounding CpG sites were analysed
using the Kruskal–Wallis H test. The association between
CpG-SNPs and DNA methylation was based on an ad-
ditive genetic model and p values were adjusted for
multiple testing using Bonferroni correction and signifi-
cance threshold <0.05 after Bonferroni correction was
considered significant. Statistical calculations were per-
formed using IBM SPSS statistics 20 (SPSS, Chicago,
IL, USA).
Analysis of mRNA expression in human islets Expression of
mRNA was analysed in pancreatic islets from the human
donors using the GeneChip Human Gene 1.0 ST array from
Affymetrix (Santa Clara, CA, USA) as described previously
by Olsson et al [14]. The array data were summarised and
normalised using the robust multi-array analysis method and
the software ‘Expression Console’ (Affymetrix), and were
corrected for batch effects within the array data using
COMBAT [15].
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and mRNA expression in hu-
man islets Associations between type 2 diabetes CpG-SNPs
that exhibit differential DNA methylation and mRNA ex-
pression in the human islets were analysed using linear
regression assuming an additive model. In the linear model,
mRNA expression values were used as quantitative traits,
SNP genotypes were encoded as 0, 1 or 2 according to their
minor allele, and sex, age, BMI, islet purity and islet culture
days were included as covariates. The analysis was restrict-
ed to genes located within a maximum distance of 500 kb
from a CpG-SNP site. The analysis was performed by using
the Matrix expression quantitative trait loci (eQTL) R pack-
age [16].
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and alternative mRNA
splicing The Gene Array Analyzer (GAA) [17] was used
together with mRNA expression data from the GeneChip
Human Gene 1.0 ST array (Affymetrix) to test if type 2
diabetes CpG-SNPs that exhibit differential DNA methyla-
tion are associated with alternative splicing events in human
islets. Each exon on the GeneChip Human Gene 1.0 ST
array is covered by at least two probes, which is why the
expression data from these arrays can be used to analyse
alternative splicing events, as previously described [17]. The
Design problems (n=1)
Failed assays (n=2)
T2D GWAS SNPs (n=40):







Illumina 750k and TaqMan
Identify CpG-SNPs associated
with DNA methylation
Identify CpG-SNPs associated with
expression, splicing and hormones
Fig. 1 Flow chart of the study design and SNP selection process. T2D,
type 2 diabetes
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gene-level-normalised intensity was calculated for each ex-
on and splice index and the Student’s t test was applied for
identification of differentially expressed exons between dif-
ferent type 2 diabetes CpG-SNP groups.
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and measures of islet
function Insulin and glucagon secretion as well as insulin
content were used as measures of islet function. Glucose-
stimulated insulin release was measured as stimulation in-
dex (SI) in static incubations of human islets as previously
described [18]. Glucagon secretion from human islets was
measured after stimulation with either 8.3 or 16.7 mmol/l
glucose for 1 h. Twelve human islets in eight replicates per
culture condition were pre-incubated in HEPES-balanced
salt solution (HBSS). Thereafter, glucose was added to a
final concentration and islets incubated for 1 h. The super-
natant fraction was immediately removed and the glucagon
concentration in the medium was measured by RIA
(Millipore, Billerica, MA, USA). Insulin content in homo-
genised human islets was assessed by ELISA (Mercodia,
Uppsala, Sweden) and then normalised to the total DNA in
each sample as determined by fluorometric assay (Quant-iT
Picogreed, Invitrogen Molecular Probes, Stockholm,
Sweden). Associations between type 2 diabetes CpG-SNPs
that exhibit differential DNA methylation and insulin secre-
tion, glucagon secretion and insulin content in the human
islets were analysed using linear regression, assuming an
additive model adjusted for the covariates age, sex and BMI.
Identification of SNPs in LD with 19 type 2 diabetes CpG-
SNPs SNP annotation and proxy (SNAP) search [19] was
used to identify SNPs in LD with the 19 type 2 diabetes
CpG-SNPs. The search was based on genotype data from
the 1000 Genomes project with the Centre d'Etude du
Polymorphisme Humain (Utah residents with northern and
western European ancestry) (CEU) population panel. An r2
threshold >0.8 from pairwise LD calculations and a distance
limit of 500 kb from the query SNP were set as inclusion
criteria for LD SNPs. To determine if the identified LD
SNPs were CpG-SNPs, the DNA sequences were retrieved
from the dbSNP database (www.ncbi.nlm.nih.gov/snp/). A
SNP was considered to be a CpG-SNP if it introduces or
removes a CpG site.
Results
Identification of CpG-SNPs associated with type 2
diabetes Of the 40 type 2 diabetes genome-wide-
associated SNPs [2, 20–30], 19 (48%) of the risk alleles
introduce or remove a CpG site and are considered CpG-
SNPs (Table 2). Of these 19 CpG-SNPs associated with type
2 diabetes, ten SNPs are intergenic, five are located in
introns and four are coding SNPs (Table 2).
CpG-SNPs associated with type 2 diabetes affect DNA
methylation in human pancreatic islets The impact of these
19 type 2 diabetes-associated CpG-SNPs on DNA methyl-
ation in pancreatic islets from 84 human donors was exam-
ined (Fig. 1 and Table 2). Successful DNA methylation data
were generated for 16 of the 19 type 2 diabetes-associated
CpG-SNP loci representing the candidate genes CDKAL1,
CHCHD9, DUSP8, IRS1, SRR, TSPAN8, CDKN2A, HHEX,
PPARG, TCF7L2, DUSP9, SLC30A8, HMGA2, KCNQ1,
ADCY5 and WFS1 in human islets (Fig. 1). DNA methyla-
tion data were also generated for a total of 22 CpG sites
located near the CDKN2A, HHEX, PPARG, TCF7L2,
DUSP9, SLC30A8, HMGA2, KCNQ1, ADCY5 and WFS1
type 2 diabetes-risk SNPs. As a result of either design or
technical problems, DNA methylation data could not be gen-
erated for the remaining three type 2 diabetes CpG-SNP loci
representing KCNJ11, ZBED3 and CDC123 (Fig. 1).
We then tested if the type 2 diabetes-associated CpG-
SNPs are associated with differential DNA methylation of
the CpG-SNP sites as well as the surrounding CpG sites. All
16 type 2 diabetes CpG-SNPs that generated successful data
were associated with differential DNA methylation of the
CpG-SNP site in the human islets (p≤2.3×10−5, Fig. 2a–p
and ESMTable 2). In addition, six CpG-SNP loci representing
CDKN2A, TCF7L2, HMGA2, KCNQ1, ADCY5 and WFS1
were associated with differential DNA methylation of sur-
rounding CpG sites (p<0.05, Fig. 2a–p and ESM Table 2).
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and mRNA expression in hu-
man islets Increased DNA methylation of certain genome
regions may silence gene transcription [7, 11]. We therefore
tested if carriers of CpG-SNP genotypes associated with
increased DNA methylation have decreased mRNA expres-
sion of genes located in regions 500 kb up- and downstream
of the CpG-SNPs using microarray expression data from the
human islets. We found that the CpG-SNP genotype carriers
of rs391300 and rs5945326 that have increased DNA meth-
ylation also have decreased mRNA expression of RPA1 and
AVPR2, respectively, in human islets (Table 3).
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and alternative splicing events
in human islets There are further data supporting a role for
DNA methylation in alternative splicing events [31]. We
hence tested if the type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and are located in gene
introns or exons are associated with differentially expressed
exons assessed by splice index using Gene Array Analyzer
(http://GAA.mpi-bn.mpg.de) [17]. We found that type 2
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Fig. 2 Histograms showing the mean degree of DNA methylation for
each genotype of 16 type 2 diabetes-associated CpG-SNPs and sur-
rounding CpG sites in human pancreatic islets of 84 donors (a–p).
*p<0.05 for associations between the CpG-SNP and DNA methylation
after Bonferroni correction (n=16). Data are presented as mean ± SD
Table 3 Associations between type 2 diabetes CpG-SNPs that exhibit differential DNA methylation and mRNA expression in human pancreatic
islets
Chr. SNP ID Gene SNP location Genotype n Gene expression
Mean ± SD β (SEM) p value
17 rs391300 RPA1 ∼413.4 kb down A A 12 574.3±54.3 −0.056 (0.027) 0.040
A G 47 562.1±57.4
G G 22 537.1±60.5
X rs5945326 AVPR2 ∼268.1 kb up A A 50 66.8±9.0 −0.052 (0.024) 0.034
A G 9 64.1±5.1
G G 22 62.3±8.7
Data are expressed as mean ± SD of unlogged gene expression values
β (SEM) and p values are based on a linear regression of log2 values of gene expression adjusted for age, sex, BMI, islet purity and islet culture
days
Chr., chromosome
Diabetologia (2013) 56:1036–1046 1041
diabetes CpG-SNPs located in SLC30A8, WFS1, CDKAL1
and TCF7L2 were associated with alternative splicing
events in the respective gene in the human islets (Table 4).
Associations between type 2 diabetes CpG-SNPs that exhibit
differential DNA methylation and measures of islet
function We further examined if the type 2 diabetes CpG-
SNPs that exhibit differential DNA methylation were asso-
ciated with measures of islet function. As type 2 diabetes is
characterised by decreased glucose-stimulated insulin secre-
tion and elevated glucagon levels [32], we tested if the risk
alleles of the type 2 diabetes CpG-SNPs were associated
with lower insulin content and/or secretion as well as ele-
vated glucagon secretion from the human islets. The CpG-
SNPs rs11708067 (ADCY5) and rs5015480 (HHEX) were
associated with insulin secretion, while rs11708067
(ADCY5) and rs2237895 (KCNQ1) were associated with
glucagon secretion (Table 5). Moreover, the type 2 diabetes
CpG-SNP rs564398 (CDKN2A) was associated with insulin
content in the human islets (Table 5).
Identification of CpG-SNPs in LD with the 19 type 2
diabetes-associated CpG-SNPs We next performed a sys-
tematic analysis to examine if the 19 type 2 diabetes CpG-
SNPs are in LD with any nearby SNPs and if any of these
LD SNPs are also CpG-SNPs using SNAP search [19]
together with genotype data from the 1000 Genomes proj-
ect. We identified a total of 295 SNPs, of which 91 are CpG-
Table 4 Associations between CpG-SNPs that exhibit differential DNA methylation and alternative splicing events, assessed by splice index in
human pancreatic islets






AA vs Aa AA vs aa Aa vs aa
Splice index p value Splice index p value Splice index p value
rs13266634 SLC30A8 8148003 8148008 Exon 3 0.066 0.39 0.34 0.031 0.28 0.085
8148003 8148011 Exon 7 −0.005 0.88 −0.14 0.030 −0.13 0.039
8148003 8148015 Exon 11 −0.056 0.21 −0.26 0.0048 −0.21 0.028
rs1801214 WFS1 8093906 8093909 Exon 2 −0.029 0.70 0.20 0.040 0.23 0.011
rs7754840 CDKAL1 8117140 8117152 Exon 10 −0.039 0.40 −0.15 0.035 −0.12 0.10
rs7901695 TCF7L2 7930537 7930538 Exon 1 −0.38 0.045 −0.34 0.56 0.033 0.96
AA, homozygotes for major allele; Aa, heterozygotes; aa, homozygotes for minor allele; p value, based on t test of gene-level-normalised intensity of exon
Table 5 Associations between type 2 diabetes CpG-SNPs that exhibit differential DNA methylation and measures of islet function including
glucose-stimulated insulin secretion (SI), glucagon secretion and insulin content in human pancreatic islets
Phenotype SNP ID Candidate gene Genotype n Mean ± SD β (SEM) p value
Insulin secretion (SI) rs11708067 ADCY5 AA 48 7.1±7.8 0.18 (0.08) 0.031
AG 28 13.2±20.1
GG 2 16.2±17.7
rs5015480 HHEX GG 21 5.4±5.9 0.14 (0.08) 0.036
AG 44 9.5±10.1
AA 13 16.1±27.1
Glucagon (pg islet−1h−1, 8.3 mmol/l glucose)a rs11708067 ADCY5 AA 3 7.0±2.6 −0.64 (0.15) 0.027
AG 5 3.2±2.7
Glucagon (pg islet−1h−1, 16.7 mmol/l glucose) rs2237895 KCNQ1 AA 17 8.6±10.6 0.26 (0.12) 0.042
AC 19 23.6±26.1
CC 8 35.2±42.2
Insulin content (ng/ng DNA) rs564398 CDKN2A AA 24 4.5±2.5 0.10 (0.04) 0.023
AG 36 6.9±3.9
GG 11 6.5±4.1
Data are expressed as mean ± SD. β (SEM) and p values are from linear regression adjusted for age, sex and BMI as covariates
a Data available from a subset of the cohort
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SNPs in strong LD (r2>0.8) with the 19 type 2 diabetes
CpG-SNPs (Table 6). The 295 LD SNPs can be found in
ESM Table 3. We further tested if CpG-SNPs that are in LD
with type 2 diabetes CpG-SNPs also give rise to differential
DNA methylation in the CpG-SNP site. Three LD CpG-
SNPs were selected for this analysis based on their location
near a type 2 diabetes CpG-SNP with a large number of LD
CpG-SNPs. DNA methylation was subsequently analysed in
the three CpG-SNPs rs4712523, rs3821943 and rs12778642,
which are in strong LD with the type 2 diabetes CpG-SNPs
rs7754840 (CDKAL1), rs1801214 (WFS1) and rs5015480
(HHEX), respectively. The three analysed LD CpG-SNPs
were associated with differential DNA methylation in the
CpG-SNP site in human islets (Fig. 3a–c, ESM Table 4) and
the differences in methylation were similar to the data seen in
respective type 2 diabetes CpG-SNPs (Fig. 2).
Discussion
Approximately 40 type 2 diabetes-associated loci have been
identified by GWASs [2]. Furthermore, a number of studies
that have aimed to unravel the physiological mechanisms
through which these loci predispose to diabetes have shown
that most of the identified loci act through impaired insulin
secretion while some affect insulin sensitivity [3, 33].
However, the molecular mechanisms through which these
SNPs influence gene function and disease pathology are
largely unknown. In this study, we found that 19 of 40
SNPs associated with type 2 diabetes introduce or remove
CpG sites, which are potential sites for DNA methylation.
Many of these CpG-SNPs have previously been associated
with impaired insulin secretion, hence the focus on these
CpG-SNPs in human pancreatic islets [2]. Interestingly, we
show that all analysed type 2 diabetes CpG-SNPs are asso-
ciated with differential DNA methylation of the CpG-SNP
sites in human pancreatic islets. We also found that six of the
CpG-SNPs are associated with differential DNA methyla-
tion of surrounding CpG sites. Moreover, some of the type 2
diabetes CpG-SNPs that exhibit differential DNA methyla-
tion are associated with gene expression, alternative splicing
events and hormone secretion in the human islets. The 19
type 2 diabetes CpG-SNPs are in strong LD with 91 addi-
tional CpG-SNPs that also seem to exhibit differential DNA
methylation at the SNP site. Our data suggest that interac-
tions between genetic and epigenetic factors may affect type
2 diabetes as several risk SNPs that influence islet function,
such as TCF7L2, HHEX, CDKN2A, SLC30A8, CDKAL1,
Table 6 The number of SNPs and CpG-SNPs in LD with the 19
identified type 2 diabetes CpG-SNPs




rs11708067 ADCY5 14 2
rs12779790 CDC123 2 1
rs13266634 SLC30A8 5 3
rs13292136 CHCHD9 22 3
rs1531343 HMGA2 26 5
rs1801214 WFS1 94 41
rs1801282 PPARG 21 7
rs2237895 KCNQ1 0 0
rs2334499 DUSP8 4 0
rs391300 SRR 2 0
rs4457053 ZBED3 4 0
rs5015480 HHEX 11 7
rs5219 KCNJ11 15 5
rs564398 CDKN2A 22 6
rs5945326 DUSP9 1 0
rs7578326 IRS1 9 1
rs7754840 CDKAL1 30 7
rs7901695 TCF7L2 7 2
rs7961581 TSPAN8 6 1
∑295 ∑91
Identification of LD SNPs based on 1000 Genome project in the CEU
population with a distance limit of ±500 kb from candidate SNP. CpG-
SNPs identified based on sequence data from dbSNP
LD, r2 >0.8
Fig. 3 Histograms showing the mean degree of DNA methylation
in human islets for each genotype of CpG-SNPs in LD with three
type 2 diabetes-associated CpG-SNPs: (a) rs7754840 (CDKAL1);
(b) rs1801214 (WFS1); and (c) rs5015480 (HHEX). *p<0.05 for associ-
ations between the CpG-SNP and DNA methylation. Data are presented
as mean ± SD
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ADCY5 and WFS1 [2, 3], are CpG-SNPs that exhibit differ-
ential DNA methylation in human islets.
An important characteristic of CpG sites is their mutability,
which makes them hotspots for human genetic disease [34].
Indeed, more than 30% of all point mutations in humans are a
consequence of DNA methylation [35]. While hydrolytic
deamination of cytosines produces uracil, which is a foreign
base in the DNA sequence that is identified and fixed by the
DNA repair system, methylated cytosines are hydrolytically
deaminated to thymines, which are not identified as foreign
and hence less likely to be repaired, resulting in a C→T
transition [34], which is the most common point mutation in
humans [34, 36]. Indeed, of the approximately 2.3 million C/T
or G/A autosomal SNPs identified by the second-phase
HapMap database, 34% are located within a CpG site [37]
and some have also been associated with disease [12, 13, 36,
38]. However, to our knowledge no previous study has exam-
ined if the 40 type 2 diabetes-associated SNPs are CpG-SNPs.
CpG-SNPs may provide a possible molecular mechanism
through which SNPs can influence a phenotype. One sug-
gested scenario is that CpG-SNPs can affect local DNA
methylation which, in turn, affects the expression of a gene
by allowing or preventing the binding of CpG methyl-
binding proteins [13]. Another scenario is that CpG-SNPs
may affect transcriptional splicing via differential DNA
methylation. Indeed, DNA methylation has been shown to
play a role in the regulation of splicing and it has been
suggested that exon DNA methylation may aid the splico-
some in distinguishing exons from introns [31].
Interestingly, recent studies of TCF7L2 variants have sug-
gested that SNPs located in introns can affect gene function
through splicing [39]. Intragenic DNA methylation has also
been suggested to play a direct role in reducing or enhancing
transcription elongation efficiency via alternative promoters
located within gene bodies [40] or indirectly by regulating
non-coding transcripts that then affect the transcription of
the associated genes [41, 42]. Another possible mechanism
is by affecting the recombination rate [37]. Our data suggest
that differential DNA methylation in CpG-SNP sites of
human islets may influence gene expression of nearby genes
as well as alternative splicing when the CpG-SNP is located
within a gene. This may subsequently affect islet function.
Two of the analysed type 2 diabetes CpG-SNPs that show
differential DNA methylation (rs391300 and rs5945326) are
associated with differential gene expression and 50% of the
analysed type 2 diabetes CpG-SNPs located in introns and/
or exons affect alternative splicing events in the human
islets. Moreover, several type 2 diabetes CpG-SNPs are
associated with measures of islet function. It should be taken
into account that our study included 84 donors of human
islets and although this is one of the largest human islet
cohorts existing, for some of the type 2 diabetes CpG-SNPs
there are only a few or no donors homozygous for the rare
variant, which may explain the lack of power to identify
associations between more CpG-SNPs and gene expression
or hormone measures. Other reasons for the lack of associ-
ations between some of the type 2 diabetes CpG-SNPs and
the analysed phenotypes could be that some of the type 2
diabetes CpG-SNPs do not affect gene expression or hor-
mone secretion but possibly cause downstream modifica-
tions of mRNA or protein translation, or other phenotypes
such as genome stability and recombination. Future studies
are needed to fully elucidate the role of differential DNA
methylation in CpG-SNPs.
SNPs within TCF7L2 confer the highest genetic risk of
developing type 2 diabetes [21, 24, 43–45]. While
rs7903146 within intron 4 of TCF7L2 is the most studied
SNP, there are multiple SNPs in strong LD with rs7903146,
including rs7901695, that also show strong associations
with type 2 diabetes [46, 47]. The aim of our study was to
examine if known type 2 diabetes SNPs introduce or remove
CpG sites. The SNP rs7903146 is not a CpG-SNP. However,
other TCF7L2 SNPs associated with type 2 diabetes, includ-
ing rs7901695, delete CpG sites and we hence included
rs7901695 data in our study. While rs7901695 and
rs7903146 are in full LD (r2=1) in the islet donors included
in our study, these two SNPs are in strong, but not full, LD
in the CEU population based on genotype data from the
1000 genome project (r2=0.892).
The causal variants remain to be identified for a number of
the identified type 2 diabetes SNPs [2]. It should further be
noted that many of the type 2 diabetes SNPs have been
connected to a gene name based on location and/or biological
relevance, rather than showing association with expression of
that particular gene. Several of the type 2 diabetes SNPs may
hence be associated with expression of genes other than the
one to which they have been assigned. Indeed, we found that
rs391300 and rs5945326 are associated with mRNA expres-
sion of RPA1 and AVPR2, respectively, in the human islets.
RPA1 encodes replication protein A1, which is involved in
DNA replication, and AVPR2 encodes the vasopressin recep-
tor, type 2, which belongs to the seven-transmembrane-
domain G-protein-coupled receptor (GPCR) superfamily that
stimulates adenylate cyclase. However, whether these two
genes affect islet function remains to be tested.
We found that a CpG-SNP may not only be associated
with differential DNA methylation of the CpG-SNP site
itself, but may also be associated with DNA methylation
of surrounding CpG sites. These results are in agreement
with another study that has reported CpG-SNPs to affect
DNA methylation of other, nearby, CpG sites and not only
within the CpG-SNP site [48]. The observed correlation in
DNA methylation between the CpG-SNP site and the adja-
cent CpG sites may be due to the presence of two active sites
on DNMT3a, which allow for the simultaneous methylation
of two CpG sites separated by one DNA helical turn [49].
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We also found 91 CpG-SNPs out of a total of 295 SNPs in
strong LD with the 19 type 2 diabetes-associated CpG-
SNPs. The LD CpG-SNPs seem to affect the DNA methyl-
ation pattern in a similar fashion to the type 2 diabetes CpG-
SNP. Genome regions with a large number of CpG-SNPs in
LD are therefore likely to affect the chromatin structure and
subsequently gene function.
Together, this study demonstrates how genetic (SNPs)
and epigenetic (DNA methylation) mechanisms can interact
and our data provide a possible molecular mechanism
through which type 2 diabetes-associated SNPs that intro-
duce or remove CpG sites may affect gene function through
differential DNA methylation and consequently the pheno-
type of the disease.
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